BD Completes Asset Divestitures to Merit Medical

February 15, 2018 |

1 min read

The completion of the divestitures satisfies the remaining contingencies within the previously received regulatory approvals in the U.S., Europe and China for BD’s acquisition of C. R. Bard which was completed on Dec. 29, 2017.

Divestitures Satisfy All Contingencies from Regulatory Authorities Related to Acquisition of C. R. Bard, Inc.

[15-February-2018]

FRANKLIN LAKES, N.J., Feb. 15, 2018 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and Aspira^® product line to Merit Medical Systems, Inc. following receipt of all required regulatory approvals for such divestitures.

The completion of the divestitures satisfies the remaining contingencies within the previously received regulatory approvals in the U.S., Europe and China for BD’s acquisition of C. R. Bard, Inc., which was completed on Dec. 29, 2017.

This sale will not have a material impact on revenue or earnings for fiscal 2018.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

 Contacts: Troy Kirkpatrick Monique N. Dolecki BD Public Relations BD Investor Relations 858.617.2361 201.847.5378 troy.kirkpatrick@bd.com Monique_Dolecki@bd.com

View original content with multimedia:http://www.prnewswire.com/news-releases/bd-completes-asset-divestitures-to-merit-medical-300598804.html

SOURCE BD (Becton, Dickinson and Company)

Company Codes: NYSE:BDX